KRAS and cancer: Moreover, expanding patient benefit across a wider spectrum of KRAS-driven cancers will be fueled by emerging classes of KRAS drugs with greater potency, broader KRAS mutant coverage, and distinct modes of action, such as by targeting the active GTP-bound (ON) state of KRAS (53,54).